NCT07700212
A Phase 1 Trial Of Safety And Initial Efficacy Of Vagal Nerve Blockade For Cancer-Induced Cachexia In Patients With Metastatic Pancreatic Adenocarcinoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 2 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Eligibility criteria expanded, about 19 words
- Start date changed from estimate of Sep 30, 2026 to Sep 25, 2026
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Safety and Adverse Events (AEs)
Timeframe: Through study completion; an average of 1 year.
Arms and interventions
Treatment with OnVagus deviceExperimental
Device will be applied by participant/caregiver daily for 30 min/day for 4 weeks; if well tolerated, 30 min twice per day for the following 4 weeks.
Devices: Transcutaneous LFVB (tLFVB)
Sites
1 site in 1 country
- UT MD AndersonHouston, Texas, United States